Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 7/20 | 0.47 |
| ▸ | ACHE | P22303 | 7/20 | 0.47 |
| ▸ | BACE1 | P56817 | 7/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840370 | 1.00 | KDM1A (0.48) | KDM1ABCHEACHEBACE1CXCR3 | |
| SCHEMBL16497860 | 1.00 | KDM1A (0.48) | KDM1ABCHEACHEBACE1CXCR3 | |
| SCHEMBL2850700 | 1.00 | KDM1A (0.48) | KDM1ABCHEACHEBACE1CXCR3 | |
| SCHEMBL76455 | 0.84 | KDM1A (0.46) | KDM1ABCHEACHEBACE1KCNH2 | |
| SCHEMBL68520 | 0.84 | KDM1A (0.46) | KDM1ABCHEACHEBACE1KCNH2 | |
| SCHEMBL66451 | 0.81 | CACNA1B (0.44) | KDM1ABCHEACHEBACE1KCNH2 | |
| SCHEMBL16497761 | 0.81 | CACNA1B (0.51) | KCNH2CACNA1BGRIN2B | |
| SCHEMBL2421730 | 0.81 | CACNA1B (0.51) | KCNH2CACNA1BGRIN2B | |
| SCHEMBL2420238 | 0.81 | CACNA1B (0.51) | KCNH2CACNA1BGRIN2B | |
| SCHEMBL11413096 | 0.78 | FUCA1 (0.60) | BCHEACHEBACE1FUCA1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | claimed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | KDM1A 1644/4885BCHE 1530/4885ACHE 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.